Search Results

Gossamer Bio, Inc. and Chiesi Farmaceutici S.p.A announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.

Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the presentation of eight abstracts from Chiesi’s global respiratory research portfolio at the American Thoracic Society (ATS) 2024 International Conference in San Diego from May 17-22, 2024.

Chiesi Farmaceutici S.p.A. announced the completion of the acquisition of Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.

Chiesi Farmaceutici S.p.A. and Amryt Pharma Plc announced that the companies have entered into a definitive agreement under which Chiesi will acquire Amryt.

Chiesi USA, Inc. today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.

Nemysis is pleased to announce that it has entered into a Strategic Alliance Agreement with Bruno Farmaceutici S.p.A. for the mutual advancement of the portfolio and sales of each company.

Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici.

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced updates from their rare endocrine disease portfolio with two late-breaking poster presentations and one oral presentation during the Endocrine Society’s ENDO 2024 Meeting that was held June 1-4, 2024, in Boston, Massachusetts.

Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.

Chiesi Farmaceutici S.p.A and Haisco Pharmaceutical Group Co.Ltd announced the execution of a Licensing Agreement to develop, manufacture, and commercialise outside China and adjacent territories HSK31858, a novel, reversible dipeptidyl peptidase 1 inhibitor for respiratory diseases.